[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44.
[2] Zhang Q, Shi B, Wu L. Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study[J]. PeerJ, 2022, 10: e13519.
[3] Ekpanyapong S, Reddy K R. Infections in cirrhosis[J]. Curr Treat Options Gastroenterol,2019, 17(2): 254-270.
[4] Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications[J].Liver Int, 2013, 33(1): 31-39.
[5] Sipeki N, Antal-Szalmas P, Lakatos P L, et al. Immune dysfunction in cirrhosis[J]. World J Gastroenterol, 2014, 20(10): 2564-2577.
[6] Wilde B, Katsounas A. Immune dysfunction and albumin-related immunity in liver cirrhosis[J]. Mediators Inflamm, 2019, 2019: 7537649.
[7] Nischalke H D, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis[J]. J Hepatol, 2011, 55(5): 1010-1016.
[8] Mucke M M, Rumyantseva T, Mucke V T, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality[J]. Liver Int, 2018, 38(4): 645-653.
[9] Shalimar, Rout G, Jadaun S S, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients[J]. Dig Liver Dis, 2018, 50(11): 1225-1231.
[10] Wang C, Ma D Q, Luo S, et al. Incidence of infectious complications is associated with a high mortality in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. World J Clin Cases, 2019, 7(16): 2204-2216.
[11] Bhattacharya C, Das-Mondal M, Gupta D, et al. Infection in cirrhosis: A prospective study[J]. Ann Hepatol, 2019, 18(6): 862-868.
[12] Fernandez J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe[J]. J Hepatol, 2019, 70(3): 398-411.
[13] Schultalbers M, Tergast T L, Simon N, et al. Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites[J]. United European Gastroenterol J, 2020, 8(5): 567-576.
[14] Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380 e10.
[15] Verma N, Singh S, Taneja S, et al. Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections[J]. Liver Int, 2019, 39(3): 503-513.
[16] 郭建琼, 程玲, 刘洪利, 等. 163例慢性重型乙型病毒性肝炎合并自发性细菌性腹膜炎的临床分析[J]. 第三军医大学学报, 2011, 33(21): 2240-2243.
[17] 陈曦, 王移欢, 段绍琪, 等. 肝衰竭合并自发性细菌性腹膜炎的临床分析[J]. 川北医学院学报, 2021, 36(4): 445-448.
[18] 项志雄, 宁国强, 邓辉球, 等. PCT、hs-CRP、IL-4诊断及评估肝硬化失代偿期自发性细菌性腹膜炎的效能[J]. 中华医院感染学杂志, 2022, 32(15): 2254-2258.
[19] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
[20] 陈仁, 廖金瑶, 陈文莉, 等. 重型肝炎合并肺部感染患者相关危险因素的分析以及防治对策[J]. 中华疾病控制杂志, 2016, 20(10): 1029-1031+1035.
[21] Shi Y, Huang Y, Zhang T T, et al. Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)[J]. J Thorac Dis, 2019, 11(6): 2581-2616.
[22] Bonnel A R, Bunchorntavakul C, Reddy K R J C G, et al. Immune dysfunction and infections in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2011, (9): 9.
[23] Fernandez J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880.
[24] 李皇, 卢平宣. 重症肝病患者并发败血症感染菌及其耐药性分析[J]. 广西医学, 2009, 31(4): 567-569.
[25] 梁晓岳, 唐锡尔, 胡耀仁. 重型肝炎、肝硬化医院感染败血症临床分析[J]. 中华传染病杂志, 2005, (3): 204-206.
[26] Xie Y, Tu B, Zhang X, et al. Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection[J]. Oncotarget, 2018, 9(3): 3980-3995.
[27] Cai Q, Liu W, Zhu M, et al. Microbial infections as a trigger for acute-on-chronic liver failure: a review[J]. Med Sci Monit, 2019, 25: 4773-4783.
[28] 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10): 754-763.
[29] Fernandez J, Bert F, Nicolas-Chanoine M H. The challenges of multi-drug-resistance in hepatology[J]. J Hepatol, 2016, 65(5): 1043-1054.
[30] Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients[J]. Intensive Care Med, 2019, 45(6): 789-805.
[31] Ullmann A J, Aguado J M, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24 Suppl 1: e1-e38.
[32] Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis[J].Nutrition (Burbank, Los Angeles County, Calif), 2001, 17(6): 445-450. |
